Zacks Investment Research Lowers Tetraphase Pharmaceuticals (TTPH) to Sell

Tetraphase Pharmaceuticals (NASDAQ:TTPH) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

According to Zacks, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. “

Several other research firms also recently weighed in on TTPH. HC Wainwright raised their price objective on Tetraphase Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, November 6th. ValuEngine downgraded Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. BMO Capital Markets raised their price objective on Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the company an “outperform” rating in a research note on Wednesday, October 4th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Tetraphase Pharmaceuticals in a research note on Tuesday, September 12th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Sunday, September 17th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $15.15.

Shares of Tetraphase Pharmaceuticals (TTPH) opened at $6.33 on Friday. The company has a market capitalization of $323.40, a P/E ratio of -2.21 and a beta of 2.51. Tetraphase Pharmaceuticals has a 1-year low of $3.57 and a 1-year high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) EPS for the quarter, meeting the consensus estimate of ($0.63). Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. The business had revenue of $4.10 million during the quarter, compared to analysts’ expectations of $1.59 million. During the same period last year, the firm earned ($0.58) EPS. The company’s quarterly revenue was up 355.6% compared to the same quarter last year. research analysts anticipate that Tetraphase Pharmaceuticals will post -2.88 EPS for the current year.

In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 8,750 shares of the firm’s stock in a transaction on Tuesday, October 31st. The stock was sold at an average price of $6.03, for a total transaction of $52,762.50. Following the completion of the transaction, the insider now owns 8,750 shares of the company’s stock, valued at $52,762.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director L Patrick Gage purchased 3,880 shares of the company’s stock in a transaction on Wednesday, November 29th. The shares were bought at an average cost of $6.45 per share, with a total value of $25,026.00. Following the transaction, the director now directly owns 38,880 shares of the company’s stock, valued at approximately $250,776. The disclosure for this purchase can be found here. Company insiders own 5.50% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in TTPH. SG Americas Securities LLC purchased a new position in Tetraphase Pharmaceuticals during the third quarter worth $107,000. Brighton Jones LLC purchased a new position in Tetraphase Pharmaceuticals during the third quarter worth $108,000. AXA purchased a new position in Tetraphase Pharmaceuticals during the second quarter worth $132,000. Virtu KCG Holdings LLC purchased a new position in Tetraphase Pharmaceuticals during the second quarter worth $147,000. Finally, Voya Investment Management LLC increased its position in Tetraphase Pharmaceuticals by 17.8% during the second quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 3,104 shares in the last quarter. 58.15% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Zacks Investment Research Lowers Tetraphase Pharmaceuticals (TTPH) to Sell” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/01/06/zacks-investment-research-lowers-tetraphase-pharmaceuticals-ttph-to-sell.html.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Get a free copy of the Zacks research report on Tetraphase Pharmaceuticals (TTPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply